Prometrium and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

Why This Interaction Gets Flagged

Prometrium and PPIs share metabolic real estate in the liver. That overlap is the reason drug interaction checkers flag the combination, even though the clinical consequence is usually minor.

Micronized progesterone undergoes extensive first-pass hepatic metabolism, primarily through CYP3A4, with secondary contributions from CYP2C19 and CYP2C9 [1]. Omeprazole is both a substrate and a moderate inhibitor of CYP2C19, while also weakly inhibiting CYP3A4 at higher doses [2]. When both drugs compete for CYP2C19 binding, progesterone clearance may slow, raising its circulating levels by a modest but measurable amount. The FDA-approved Prometrium label notes that "drugs known to inhibit hepatic cytochrome P450 3A4 ... may increase plasma concentrations of progesterone" [1]. CYP2C19 inhibition from omeprazole adds a second, parallel brake on metabolism.

Pantoprazole behaves differently. It is a weak CYP2C19 inhibitor with less off-target enzyme binding than omeprazole [3]. This pharmacologic distinction matters clinically. A 2004 comparative study in Clinical Pharmacology & Therapeutics found that pantoprazole produced significantly less CYP2C19 inhibition than omeprazole at equivalent acid-suppressing doses [3]. For patients concerned about interaction burden, pantoprazole is the lower-risk PPI choice.

The CYP2C19 Bottleneck Explained

CYP2C19 activity varies widely across individuals, and that genetic variability shapes how much this interaction actually matters.

Approximately 2-5% of Caucasians, 12-23% of East Asians, and 2-6% of African Americans are CYP2C19 poor metabolizers [4]. These individuals already clear omeprazole slowly, producing higher omeprazole plasma levels at standard doses. Stack that on top of progesterone's own CYP2C19 metabolism, and the enzyme becomes a bottleneck. In poor metabolizers taking omeprazole 20 mg daily, omeprazole AUC values run 5- to 10-fold higher than in extensive metabolizers [2]. That degree of enzyme occupancy leaves less CYP2C19 capacity available for progesterone breakdown.

The practical result: a poor metabolizer on omeprazole 40 mg plus Prometrium 200 mg may experience more pronounced progesterone side effects (somnolence, dizziness, bloating) than an extensive metabolizer on the same regimen. This does not make the combination unsafe. It does mean that clinicians should ask about sedation and CNS effects at follow-up visits. A 2009 FDA guidance document on CYP2C19 drug interactions reinforced that "the magnitude of interaction depends on the fractional contribution of CYP2C19 to total clearance of the victim drug" [5]. For progesterone, CYP2C19's contribution is secondary to CYP3A4, which limits the ceiling of this interaction.

Gastric pH and Progesterone Absorption

PPIs raise gastric pH above 4.0 for most of the day. That shift could theoretically slow the dissolution of Prometrium's oil-filled gelatin capsule, though direct evidence for a clinically meaningful absorption change is absent.

Micronized progesterone is formulated in peanut oil within a soft gelatin shell precisely because progesterone is highly lipophilic and poorly water-soluble [1]. The capsule design already bypasses the need for acid-dependent dissolution that affects drugs like ketoconazole or iron salts. Food increases Prometrium bioavailability by 25-50% according to the prescribing information [1], which is why evening dosing with a small snack is standard practice. A 2011 review in Alimentary Pharmacology & Therapeutics cataloged drugs with pH-dependent absorption and did not list oral micronized progesterone among them [6].

Still, the theoretical concern is not zero. Patients who take PPIs on an empty stomach and then take Prometrium without food at a different time of day are layering two conditions (high pH, no dietary fat) that could each reduce progesterone absorption independently. The fix is simple: take Prometrium at bedtime with a small fat-containing snack regardless of PPI use. This single instruction neutralizes both the pH concern and the known food-effect variable.

Severity Ratings Across DDI Databases

Major drug interaction databases agree that this combination does not reach the threshold for avoidance or mandatory dose modification.

Lexicomp classifies the omeprazole-progesterone interaction as Category C (monitor therapy) [7]. Micromedex rates it as minor in severity with fair documentation [8]. The Clinical Pharmacology database flags it as a CYP-mediated interaction of "moderate" theoretical significance but "low" clinical significance. None of these sources recommend avoiding the combination. None suggest a specific dose reduction. The consensus position across all major references is: co-prescribe with awareness, not with restriction.

For pantoprazole specifically, the interaction rating drops further. Lexicomp does not generate an interaction alert for pantoprazole plus progesterone at all in most query configurations, reflecting pantoprazole's weaker CYP2C19 inhibitory profile [3]. This aligns with the European Medicines Agency's 2017 assessment that pantoprazole has a "low interaction potential" compared with omeprazole or esomeprazole [9].

Head-to-Head: Omeprazole vs. Pantoprazole With Prometrium

Not all PPIs carry the same interaction weight. Choosing the right one can minimize risk without sacrificing acid suppression.

Omeprazole inhibits CYP2C19 with a Ki of approximately 2-5 μM, while pantoprazole's Ki exceeds 30 μM [3]. That roughly sixfold difference in inhibitory potency translates directly into different interaction profiles. A crossover pharmacokinetic study published in the British Journal of Clinical Pharmacology demonstrated that pantoprazole 40 mg had no significant effect on CYP2C19 probe drug metabolism, whereas omeprazole 20 mg increased the probe's AUC by 35-40% [10].

Extrapolating to progesterone: if omeprazole raises a CYP2C19-dependent substrate's AUC by 35-40%, and CYP2C19 contributes perhaps 15-25% of progesterone's total hepatic clearance (the remainder handled by CYP3A4 and CYP2C9), the net increase in progesterone exposure from omeprazole co-administration is likely in the range of 5-10%. That magnitude sits well below the threshold most pharmacologists consider clinically relevant for a hormone with a wide therapeutic window in the HRT setting.

Pantoprazole's effect on progesterone exposure would be smaller still. For patients who need ongoing acid suppression alongside Prometrium, pantoprazole is the pharmacologically cleaner choice. Lansoprazole and rabeprazole fall between the two, with intermediate CYP2C19 inhibitory potency [3].

Monitoring and Clinical Management

Routine lab monitoring for this interaction is unnecessary. Symptom-based follow-up is sufficient for the overwhelming majority of patients.

Progesterone levels are not routinely measured in women taking Prometrium for endometrial protection during HRT. The 2022 North American Menopause Society (NAMS) position statement on hormone therapy does not recommend serum progesterone monitoring for oral micronized progesterone dosing [11]. The relevant clinical endpoints are endometrial protection (assessed by bleeding patterns and periodic ultrasound when indicated) and tolerability.

The side effects to watch for are dose-dependent progesterone effects: somnolence, dizziness, headache, and abdominal bloating [1]. If a patient newly starts a PPI (especially omeprazole at 40 mg daily) while already on Prometrium and reports increased drowsiness or CNS effects within 1-2 weeks, the PPI-mediated rise in progesterone exposure is a plausible contributor. The appropriate response is not to discontinue either drug. Three practical options exist:

Switch from omeprazole to pantoprazole, maintaining equivalent acid suppression with less CYP2C19 burden. Reduce the PPI dose if the clinical indication allows (step-down from 40 mg to 20 mg). Or shift Prometrium dosing to bedtime if not already taken then, using the somnolence as a therapeutic advantage for sleep.

Special Populations

Certain patient groups deserve extra attention when these drugs overlap. Pregnant women prescribed progesterone supplementation (for luteal phase support, for example) should avoid omeprazole in the first trimester when possible, not because of the drug interaction but because omeprazole carries a former FDA pregnancy category C rating and limited first-trimester safety data [12]. Pantoprazole or famotidine (an H2 blocker with no CYP2C19 interaction) are preferred alternatives in pregnancy.

Older adults on polypharmacy represent another group where this interaction's small effect can compound with other CYP inhibitors. A 70-year-old woman taking Prometrium 100 mg, omeprazole 40 mg, fluconazole for recurrent candidiasis, and sertraline is stacking three CYP inhibitors on top of progesterone metabolism. That stacking can push the individually minor interactions into clinically noticeable territory. The American Geriatrics Society's Beers Criteria flags prolonged PPI use in older adults independently of any progesterone interaction [13], providing an additional reason to reassess PPI necessity in this population.

Patients with hepatic impairment face the steepest interaction risk. Prometrium's prescribing information states that patients with liver dysfunction may have decreased metabolic clearance of progesterone [1]. Adding a CYP2C19 inhibitor to an already-compromised hepatic system amplifies the effect. For patients with Child-Pugh class B or C liver disease, consider using vaginal progesterone (which bypasses first-pass metabolism entirely) instead of oral Prometrium, removing the CYP-mediated interaction from the equation.

When to Consider Alternatives

The decision to switch drugs should be driven by clinical context, not by the interaction alone.

If the patient tolerates both medications without increased side effects, no change is needed. If side effects emerge, the PPI is the easier drug to swap. H2-receptor antagonists like famotidine 20-40 mg twice daily provide moderate acid suppression without CYP2C19 inhibition [14]. For patients with erosive esophagitis or Barrett's esophagus who genuinely require a PPI, pantoprazole 40 mg is the preferred agent when Prometrium is on the medication list.

On the progesterone side, vaginal micronized progesterone (available as Endometrin or compounded formulations) avoids hepatic first-pass metabolism and eliminates the CYP interaction entirely [15]. The 2017 Endocrine Society guideline on menopausal hormone therapy lists vaginal progesterone as an acceptable alternative to oral formulations for endometrial protection [16]. Vaginal administration also reduces the somnolence that oral Prometrium commonly causes, which may be beneficial for patients who dislike the sedating effect.

Serum progesterone measurement becomes reasonable only in a narrow clinical scenario: a patient on high-dose omeprazole with known CYP2C19 poor-metabolizer status who develops unexplained breakthrough bleeding or excessive sedation on Prometrium 200 mg. A trough progesterone level drawn before the evening dose can confirm whether systemic exposure is unusually high and guide a dose reduction to 100 mg nightly.